Clinical Study to Evaluate the Safety and Performance of MANTA Vascular Closure Device

Inclusion Criteria: * Candidate for non-emergent transcatheter interventional procedure via a 10-18F femoral sheath (e.g., transcatheter aortic valve replacement \[TAVR\], balloon aortic valvuloplasty \[BAV\], Abdominal Aortic Aneurysm \[AAA\] stent-graft placement) * Eligible for sheath removal in the catheterization lab * Age ≥18 years * Understand and sign the study specific written informed consent form * Able and willing to fulfill the follow-up requirements * In the Investigator's opinion, the patient is suitable for the MANTA vascular closure device, conventional hemostasis techniques and participation in an investigational trial * Patients of childbearing age with Negative Pregnancy Test within 7 days of procedure Exclusion Criteria: Baseline Exclusions: * Patients who are known to be pregnant or lactating * Patients who are immunocompromised or with pre-existing autoimmune disease * Patients who have a systemic infection or a local infection at or near the access site * Patients requiring a re-puncture at a site previously punctured within 48 hours * Patients with significant anemia (hemoglobin \< 6.5 mmol/l, Hct\<30) * Patients who are morbidly obese or cachectic (BMI \>40 or \<20) * Patients with Systolic Blood Pressure \>180 mmHg, unless Systolic Pressure can be lowered by pharmacological agents prior to closure * Patients who are currently participating in another clinical trial of an investigational device or drug that has not concluded the follow-up period * Patients in whom an antegrade puncture is performed or planned * Patients with a known bleeding disorder including thrombocytopenia (platelet count \<150 x 10\^9/L), thrombasthenia, hemophilia, or von Willebrand's disease * Patients with a femoral artery \<6 mm in diameter, femoral artery stenosis resulting in a vessel diameter \<6 mm, or patients with severe peripheral vascular disease * Common femoral artery with fluoroscopically visible calcium, as determined by Angio CT, precluding safe access in the opinion of the investigator * Patients with allergy to bovine materials, collagen and/or collagen products, or polyglycolic or polylactic acid polymers * Patients who cannot adhere to or complete the investigational protocol for any reason including but not limited to geographical residence or life threatening disease * Patients with Sheehan Disability Scale (SDS) scores \>12 * Patients punctured through a vascular graft * Patients with known allergy to stainless steel or nickel * Patients who have acute ST-elevation myocardial infarction within 48 hours prior to procedure * Patients with unilateral or bilateral lower extremity amputation * Patients with renal insufficiency (serum creatinine \>2.5 mg/dl) * Patients undergoing therapeutic thrombolysis * Patients who are unable to ambulate at baseline * Patients undergoing an interventional procedure whom are being treated with warfarin * Patients requiring a continuous oral anticoagulation therapy